Dalbavancin Versus Standard Antibiotic Therapy for Catheter-related Bloodstream Infections Due to Staphylococcus Aureus

Inclusion Criteria: * Patients aged at least 18 years; * Blood cultures positive for S. aureus, obtained within 72 hours before randomization (the date considered is the date of the sampling, not the results); * CR-BSI, defined as: * One positive blood culture AND Local signs of infection at the catheter site; OR * at least one positive blood culture obtained from the catheter and the peripheral vein; AND * A differential period between catheter versus peripheral blood culture positivity of at least 2h as recommended; AND * Same S. aureus isolate (same phenotype) identified from the catheter and the peripheral vein blood cultures; OR * One positive blood culture; AND * Strong presumption of catheter-related infection according to clinical opinion. * Intravascular catheter - implantable venous access device (port-a-cath and Piccline) - removed before randomization; * Informed consent form date and signed by the patient. Exclusion Criteria: * Polymicrobial infection; * Dalbavancin resistant strain; * More than 72 hours of active antibiotic treatment targeting S. aureus (in-vitro susceptibility) administered prior to randomization; * Patient with known valvulopathy, previous history of endocarditis, or suspicion of infective endocarditis by physician in charge; * Suspicion of any other deep focus infections, such as arthritis, pneumonia, osteomyelitis, or meningitis, presence of cerebral or peripheral emboli (arterial occlusion); * Thrombophlebitis; * Failure to remove any intravascular catheter which was present when first positive blood culture; * Signs of infection associated with quick SOFA score ≥ 2 at randomization; * Patients with foreign bodies such as: prosthetic heart valve, endovascular prosthesis, ventriculo-atrial shunt, pacemaker, or an automated implantable cardioverter defibrillator (AICD) device; * Severe liver disease (Child-Pugh C); * Severely immunocompromised patients: * Neutropenia (\< 500 neutrophils/µL) at randomization; * Hematopoietic stem cell transplantation within the past 6 months or planned during treatment period; * Solid organ transplant; * Contraindication to dalbavancin and/or glycopeptide; * Life expectancy \< 3 months; * Active injection drug user; * Pregnant or breastfeeding women; * For premenopausal women: failure to use highly-effective contraceptive methods for 1 month after receiving study drug; * Participation in other interventional trials ongoing; * Persons held in an institution by legal or official order; * Patients under legal protection; * Patients under guardianship or curators; * Patients unable to give a free and informed consent; * Patient not affiliated to a social security scheme: obligation of affiliation to a social security scheme or to be a beneficiary.